Browsing Category

Top Industry News

7360 posts

Merck & Co. To Acquire Verona Pharma for $10 Bn 
By

By
Merck & Co. has agreed to acquire Verona Pharma, a bio/pharmaceutical company focused on respiratory diseases, for $10 billion.  Through this acquisition, Merck will add Ohtuvayre (ensifentrine), a selective dual…

Sandoz Breaks Ground on New $440-M Biosimilar Mfg Site 
By

By
Sandoz has started construction of a new $440-million biosimilars production center for sterile product manufacturing in Brnik, Slovenia. The project brings the company’s total planned and ongoing investment in Slovenia…

Vetter Breaks Ground on $285-M Clinical Production Facility 
By

By
Vetter, a Ravensburg, Germany-headquartered CDMO of aseptic filling and packaging, has broken ground on a new $285-million clinical manufacturing site in Des Plaines, Illinois.   The facility is expected to be…

Hikma To Invest $1 Bn on US R&D & Mfg Expansions 
By

By
Hikma Pharmaceuticals USA has announced it will invest $1 billion by 2030 to further expand its US manufacturing and R&D capabilities in Columbus and Cleveland, Ohio, and Cherry Hill and…

Merck KGaA Completes $3.4-Bn Acquisition of SpringWorks Therapeutics 
By

By
Merck KGaA, Darmstadt, Germany, has completed its acquisition of SpringWorks Therapeutics, a Stamford, Connecticut-based commercial-stage bio/pharmaceutical company focused on severe rare diseases and cancer, for $3.4 billion. The deal was…

Supplier News: Axplora, BASF, BioSpring, Pace & More 
By

By
The latest from CDMOs, CMOs, and suppliers featuring BASF, BioSpring, Pace Life Sciences, Aenova, Future Pak, Nippon Shokubai, Azelis/Chimica e Farmaceutica, IMCD, and Axplora.   Chemicals/Chemical API Manufacturing * Axplora Announces $41-M…

Global Briefs: AbbVie, GSK & Novo Nordisk 
By

By
A roundup of news from AbbVie/Capstan Therapeutics, GSK/Boston Pharmaceuticals and Novo Nordisk. Highlights below.   M&A News * AbbVie To Acquire Capstan Therapeutics for $2.1 Bn * GSK Completes Acquisition of Liver Disease…

Novartis Completes Acquisition of Regulus Therapeutics in $1.7 Bn Deal 
By

By
Novartis has completed its acquisition of Regulus Therapeutics, a San Diego, California-based clinical-stage bio/pharmaceutical company developing microRNA therapeutics, in a deal worth up to $1.7 billion ($800 million upfront and…

Supplier News: AGC Biologics, Samsung Biologics, Bend Bioscience & More 
By

By
The latest from CDMOs, CMOs, and suppliers featuring AGC Biologics, Samsung Biologics, Bend Bioscience and Thermo Fisher Scientific/Xcell Biosciences.   Biologics Manufacturing * AGC Biologics Begins Process Development & Clinical Mfg at…

Partnering News: Gilead, Roche & More 
By

By
A roundup of bio/pharmaceutical partnering news from Gilead/Kymera Therapeutics, Roche/Maia Biotechnology and Silo Pharma/Hoth Therapeutics.  * Gilead, Kymera Therapeutics in $750-M Pact for Molecular Glue Degraders for Cancer * Roche, Maia…